Hepregen Corporation and The Hamner Institutes for Health Sciences Announce Research Partnership

Hepregen Corporation and The Hamner Institutes for Health Sciences announced execution of an agreement that provides for a research partnership between the two entities. The research effort will be led by Dr. Edward LeCluyse, Associate Investigator at The Hamner, and Dr. Michael Holsapple, newly appointed Vice President of Toxicology Product Development at Hepregen, along with Mr. Jack McGeehan, Hepregen’s Vice President of Operations. The partnership will focus on research and development efforts aimed at defining: (1) basic concepts regarding the potential for new micro-liver products and (2) new applications and assay methodologies for Hepregen’s existing micro-liver products that are already transforming pharmaceutical product development.

“This Hamner-Hepregen partnership brings together outstanding teams of scientists from both organizations, creating a cooperative effort that will yield new knowledge about how best to utilize Hepregen’s micro-liver products for safety testing associated with pharmaceutical and chemical product development,” stated Dr. Vincent Zurawski, Hepregen’s chief executive officer.

Dr. William Greenlee, President and CEO of The Hamner also commented, “This research partnership provides yet another example of The Hamner’s ability to attract and partner with high quality commercial enterprises that share our organization’s commitment to advancing human health. We look forward to working with Hepregen in our mutual quest to provide advanced, next generation predictive health tools to the pharmaceutical, chemical and related industries.”